Melanotan-1 (MT-1): The Complete Guide
A linear synthetic tridecapeptide analogue of α-MSH with selective MC1R activity. The same molecule that, as the pharmaceutical afamelanotide (Scenesse), has full FDA, EMA, and TGA approval for erythropoietic protoporphyria — one of the most extensively validated melanocortin compounds in regulated medicine.
What is Melanotan-1?
Your body has a hormone that controls how much pigment your skin makes. It's called alpha-melanocyte-stimulating hormone, but everyone shortens it to α-MSH. When your skin is exposed to UV light, your body releases more α-MSH, and α-MSH tells your skin cells to start producing melanin — the dark pigment that gives skin its colour and helps shield it from further UV damage. This is the system behind getting a suntan.
Now here's the problem researchers ran into. Natural α-MSH only survives in your body for a few seconds before enzymes break it down. That's fine for the body's purposes — α-MSH is meant to be a fast, short signal. But it makes α-MSH useless as a research tool or a medicine. If you want to study what α-MSH does over time, or use it to treat a condition, you need a version that sticks around long enough to actually work.
Melanotan 1 — usually just called MT-1 — was built to solve exactly that problem. Researchers at the University of Arizona in the late 1980s, led by chemistry professor Victor Hruby and biologist Mac Hadley, made two tiny changes to the natural α-MSH molecule. They swapped one amino acid for a sturdier version, and they replaced another amino acid with its mirror image (which sounds strange, but mirror-image amino acids are much harder for the body's enzymes to recognise and chew up). These two small structural tweaks don't change what the molecule does, but they make it last much longer. The result is a peptide that behaves like α-MSH but survives long enough to actually be useful.
Here's the part that makes MT-1 genuinely unusual in the peptide world: it's not just a research compound — it's also an approved medicine. The Australian biotechnology company Clinuvel Pharmaceuticals licensed MT-1 and developed it into a slow-release implant sold under the brand name Scenesse, with the pharmaceutical name afamelanotide. Scenesse received European approval in 2014, US FDA approval in 2019, and Australian TGA approval in 2020. Very few melanocortin peptides have made it that far through regulatory approval anywhere, let alone in three major markets.
What is Scenesse approved to treat? A rare condition called erythropoietic protoporphyria, or EPP. People with EPP have a genetic mutation that causes a light-sensitive compound to build up in their skin. The result is severe, often disabling pain whenever they're exposed to even brief sunlight. Scenesse helps these patients by stimulating their bodies to produce more protective pigment in advance, which lets them tolerate longer light exposure without the pain attacks. Researchers who order MT-1 are receiving the same molecule as Scenesse — just in research form rather than as a clinical implant.
Where MT-1 stands apart from its sister compound MT-2 is which receptor it prefers. The melanocortin receptor family has five subtypes, named MC1R through MC5R. Each one does a different job — MC1R handles pigmentation, MC3R and MC4R sit in the brain and handle motivation and appetite, MC5R sits on glands. Most synthetic peptides bind several of these receptors at once, which means they trigger several effects at once. MT-1 is unusual because it strongly prefers just one: MC1R, the receptor on skin pigment cells. This focus is what makes MT-1 useful for researchers who want to study skin pigmentation pathways without accidentally activating the brain-pathway effects that MT-2 produces.
Research Applications
Research on MT-1 covers MC1R-selective melanocortin pharmacology, melanin synthesis pathways, photoprotection mechanisms, the substantial Phase 3 clinical evidence base from Scenesse development, and ongoing dermatological investigation including vitiligo, polymorphic light eruption, and solar urticaria.
Imagine the melanocortin receptor family as five different light switches in a house — one for the skin, two for the brain, one for the glands, and one for a separate hormone system. Most synthetic peptides flip several switches at once. MT-1 mostly flips just the skin switch. Researchers use this selectivity to study what activating the skin pigment system does in isolation, without the noise of the brain-pathway effects that come with non-selective compounds like MT-2.
When MT-1 reaches a skin pigment cell, research suggests it kicks off a chain reaction inside the cell that ramps up production of melanin. But here's the interesting part: skin actually makes two different kinds of melanin. One is called eumelanin — the dark brown-black pigment that protects against UV damage. The other is called pheomelanin — a red-yellow pigment that's much less protective. Research suggests MT-1 doesn't just produce more melanin overall; it shifts the balance specifically toward eumelanin. So researchers studying photoprotection are particularly interested in MT-1 because it appears to produce the <em>protective</em> type of pigment.
Most peptides in the research space never make it into human clinical trials at all. MT-1, in its afamelanotide form, has been through three completed Phase 3 trials in 244 adult patients across 22 sites in the US and Europe (Langendonk et al. 2015, published in the New England Journal of Medicine). This is an unusual depth of human safety and effectiveness data for a research compound — most peer-reviewed peptide research is based on cell cultures or animal models, not multi-site human trials.
Research suggests MC1R activation does more than just darken skin. It also kicks off three other protective processes in the same cell. First, it switches on DNA repair machinery that fixes UV damage as it happens. Second, it turns up antioxidant activity that mops up free radicals (highly reactive molecules that damage cells). Third, it dials down inflammatory signalling. So researchers don't just study MT-1 for its pigment effects — they study it as a way to investigate all four MC1R-driven protective effects at once.
EPP is the rare condition Scenesse is approved to treat. It's caused by a mutation in a gene called FECH, which produces an enzyme involved in making haemoglobin. When FECH doesn't work properly, a compound called protoporphyrin IX builds up in the skin instead of being processed correctly. Protoporphyrin IX is photoactive, meaning it reacts violently when exposed to light, causing severe burning pain. Research suggests afamelanotide-induced melanin acts like a sunscreen built into the skin, reducing how much UV reaches the protoporphyrin and how much damage it causes. This is the scientific basis for the approved use.
Beyond EPP, MT-1 and afamelanotide have been studied in research models for other light-sensitive conditions — vitiligo (Lim et al. 2015, JAMA Dermatology), polymorphic light eruption, solar urticaria, and a rare blistering disorder called Hailey-Hailey disease (Biolcati et al. 2014). These are documented investigational research areas, not approved uses.
How Melanotan-1 Works
Structural design: Imagine α-MSH as a long piece of string. Your body's enzymes can grab that string at certain points and snip it apart in seconds. MT-1 is the same string, but with two of the links replaced by sturdier versions that the enzymes can't easily grab. At position 4, an amino acid called methionine has been swapped for one called norleucine. At position 7, the amino acid L-phenylalanine has been replaced by its mirror-image version, D-phenylalanine. The "mirror image" trick is particularly clever — enzymes are extremely picky about the shape of what they bind to, and a mirror-image amino acid is the wrong shape for them to grab. The result is that natural α-MSH disappears in seconds, while MT-1 sticks around much longer, giving researchers time to actually measure what's happening.
MC1R-preferring receptor profile: Think of melanocortin receptors as five different doorways into different rooms of a building. MC1R is the doorway to the pigmentation room. MC3R and MC4R are doorways to two different brain rooms. MC5R is the doorway to the glands room. MT-2, MT-1's sister compound, is shaped like a master key — it opens all the doors. MT-1 is shaped more like a specific key — it mostly opens just the pigmentation door, with very little activity at the others. For a researcher who wants to study what happens only in the pigmentation room without disturbing the other rooms, MT-1 is the right tool.
The cAMP-MITF-tyrosinase cascade: Once MT-1 opens the MC1R doorway on a skin pigment cell, a chain reaction starts inside the cell. Picture it as a series of dominoes falling. The first domino is an enzyme inside the cell membrane (called adenylyl cyclase) that starts producing a small messenger molecule (called cAMP). The messenger molecule then activates a master controller (a transcription factor called MITF) that decides which genes the cell should switch on. MITF flips on the gene that makes tyrosinase — and tyrosinase is the actual workhorse enzyme that builds melanin from raw materials. So the full chain looks like this: MT-1 binds the receptor → an enzyme starts producing messengers → the messengers activate a master controller → the master controller switches on the melanin-building enzyme → the cell starts making melanin. The whole sequence happens without UV light being involved. In plain terms: MT-1 convinces the skin cell to make protective pigment even when the sun isn't out.
Photoprotection mechanism: The eumelanin produced through this pathway protects skin in three different ways at once. First, it physically blocks UV light — melanin is genuinely dark, and it absorbs and scatters incoming UV before it can reach the deeper cells. Think of it as a thin black curtain inside the skin. Second, it mops up free radicals — highly reactive molecules created by UV exposure that damage DNA, proteins, and cell membranes. Eumelanin is a chemical sponge for these free radicals. Third, melanin acts as a broad-spectrum filter, dimming all wavelengths of light evenly rather than just blocking some colours. On top of all that, research suggests MC1R signalling separately stimulates DNA repair machinery and reduces inflammatory signalling — so the protective effects extend beyond just the melanin itself.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated May 2026.
Published References
- Langendonk JG, Balwani M, Anderson KE, et al. “Afamelanotide for Erythropoietic Protoporphyria.” The New England journal of medicine, 2015. PubMed
- Biolcati G, Marchesini E, Sorge F, et al. “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” The British journal of dermatology, 2015. PubMed
- Lim HW, Grimes PE, Agbai O, et al. “Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.” JAMA dermatology, 2015. PubMed
- Wensink D, Wagenmakers MAEM, Langendonk JG. “Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.” Expert review of clinical pharmacology, 2021. PubMed
Browse all Melanotan-1 research on PubMed →
Related Research Guides
More in Melanocortin Research
The cyclic sister compound from the same University of Arizona programme — non-selective across MC1R, MC3R, MC4R, MC5R. The parent structural lineage from which PT-141 was later derived.
Read guide →FDA-Approved Melanocortin AgonistThe third compound in the Melanotan family — derived from MT-2 with structural modifications producing a more selective central MC4R agonist, FDA-approved as Vyleesi in 2019.
Read guide →Anti-Inflammatory TripeptideThe C-terminal tripeptide fragment of α-MSH — approached through the anti-inflammatory pathway rather than the receptor-agonism approach of the Melanotan family.
Read guide →